CSS LLC’s BioXcel Therapeutics BTAI Stock Holding History

CSS LLC’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-313	Closed	-$105K	–	1115
2022 Q1	$105K	Buy	+313	New	+$90.7K	﹤0.01%	933
2021 Q2	–	Sell	-869	Closed	-$600K	–	1086
2021 Q1	$600K	Buy	+869	New	+$699K	0.02%	550
2020 Q3	–	Sell	-844	Closed	-$716K	–	795
2020 Q2	$716K	Buy	+844	New	+$550K	0.04%	324

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

CSS LLC's BTAI Position: Q4 2022 in Review

CSS LLC sold out of BioXcel Therapeutics (BTAI) in Q4 2022, closing a stake of 1,122 shares — an estimated $212K sold.

CSS LLC first reported a position in BTAI in Q2 2020 and held it in 10 quarters. The position peaked at $1.58M in Q1 2021. 83 funds tracked by Wall St. Rank hold BTAI as of Q4 2022.

CSS LLC reported no remaining BioXcel Therapeutics position as of Q4 2022 after selling out during the quarter.
CSS LLC sold 1,122 BioXcel Therapeutics shares in Q4 2022, an estimated $212K.
CSS LLC first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 10 quarters.
CSS LLC's BioXcel Therapeutics position peaked at $1.58M in Q1 2021.
83 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.